Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Several other research firms have also recently commented on CLLS. JMP Securities reaffirmed a market outperform rating and set a $6.00 price objective on shares of Cellectis in a research report on Friday, May 31st. Oppenheimer lowered their target price on Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a report on Wednesday, June 12th.

Cellectis Trading Up 7.9 %

Cellectis stock opened at $2.05 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.63 and a quick ratio of 1.63. Cellectis has a one year low of $0.96 and a one year high of $3.77. The stock has a market capitalization of $113.94 million, a PE ratio of -1.59 and a beta of 3.11. The business’s fifty day moving average is $2.57 and its 200 day moving average is $2.73.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, May 28th. The biotechnology company reported ($0.15) EPS for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The business had revenue of $6.50 million for the quarter. On average, sell-side analysts predict that Cellectis will post -0.54 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellectis stock. Principal Financial Group Inc. lifted its stake in Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 424,533 shares of the biotechnology company’s stock after buying an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.